Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Loncastuximab tesirine (Primary) ; Melphalan (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 11 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.
- 04 Jan 2023 Planned initiation date changed from 7 Dec 2022 to 1 Apr 2023.
- 07 Nov 2022 Planned initiation date changed from 3 Nov 2022 to 7 Dec 2022.